Get the app
US › Healthcare

Envista Holdings Corp (NVST)

US · Healthcare · Medical Instruments & Supplies

$25.17+0.84%
Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Revenue
$691.5M
Revenue YoY
+3.2%
Net profit
$508.3M
EPS
$0.40
EPS estimate
$0.35
Net margin
73.5%

EPS came in at 0.40 against a street estimate of 0.35 — a beat of 14.3%.

Key statistics

Market cap
$4.37B
P/E
42.5
Forward P/E
16.8
P/B
1.29
Book value
$19.16
EPS (TTM)
$0.64
52-week high
$30.42
52-week low
$18.77
50-day MA
$24.49
200-day MA
$25.74
Beta
0.94

Analyst view

Analysts rate Envista Holdings Corp a buy (7 buy, 8 hold, 0 sell out of 15) with an average price target of $28.69.

From the latest earnings call · 2026-08-05

CONFIDENT Envista delivered 5% core growth in Q2 with 28% EBITDA growth and 58% EPS growth. Raised full-year guidance across all metrics. Equipment & Consumables accelerating; VBP implementation expected in China second half. Q2 2026 All major geographies posted growth in Q2. China down year-to-date due to VBP compression; expected to grow moderately in second half post-VBP implementation. Analysts pressed heavily on China VBP timing, underlying growth rates, and margin drivers. Management reiterated VBP as net positive long-term based on implants VBP 1 precedent. Addressed concerns that H2 deceleration was conservative; confirmed 3.5% normalized ex adjustments. 2026-08-05…

Full summary in the app.

Shareholding

Insiders
0.56%
Institutions
120.13%

Largest institutional holders

FundStake
BlackRock Inc11.48%
Ariel Investments, LLC6.11%
Dimensional Fund Advisors, Inc.5.96%
Vanguard Portfolio Management, LLC4.66%
Vanguard Capital Management, LLC4.57%
Morgan Stanley - Brokerage Accounts4.01%
Gates Capital Management Inc3.46%
State Street Corp3.32%

Recent filings & reports

DocumentDate
Quarterly report · Q4 2026
HEADLINE NUMBERS • Third-quarter sales were $691.5 million, up from $669.9 million in the prior-year quarter. • Nine-month sales were $2,127.5 mill
2026-11-04
Results announced · Q4 2026
HEADLINE NUMBERS • Third-quarter sales were $691.5 million, up 3.2% year over year; core sales growth was 2.7%. • Adjusted diluted EPS was $0.40, up
2026-11-04
Reg FD disclosure · Q4 2026
OTHER NOTABLE POINTS • Envista Holdings Corporation (NYSE: NVST) announced on October 27, 2026, that it published its 2025 Sustainability Report. •
2026-10-27
Reg FD disclosure · Q3 2026
ENVISTA HOLDINGS CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Report Date: September 17, 2026 • Company: Envista Holdings Corporation • Ticker
2026-09-17
Board / officer change · Q3 2026
ENVISTA HOLDINGS CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Paul Keel (President and CEO) base salary increased by $200,000: from $1.1 millio
2026-08-19
Quarterly report · Q3 2026
ENVISTA HOLDINGS CORPORATION – FORM 10-Q SUMMARY For Quarterly Period Ended July 3, 2026 --- HEADLINE NUMBERS • Sales (6 months): $1,436.0 million,
2026-08-05
Results announced · Q3 2026
ENVISTA HOLDINGS CORPORATION – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Sales: $730.5 million, up 7.1% vs. Q2 2025 ($682.1 million) • Cor
2026-08-05
Board / officer change · Q2 2026
ENVISTA HOLDINGS CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • No financial metrics or performance data disclosed in this filing • Document is a
2026-06-03

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Envista Holdings Corp — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Data updated 2026-11-07.